LIFE- Independent tissue analysis confirms no adverse tissue response after six months of implantation
LIFE: Independent tissue analysis confirms no adverse tissue response after six months of implantation
2026-06-22 07:00:04
Bergen, Norway, 22 June 2026 - Lifecare ASA (LIFE) today announces that
independent histological analysis has confirmed the clinical observations from
the company's first completed six-month implant evaluation, with no adverse or
unexpected tissue response identified following six months of implantation.
On 10 June 2026, Lifecare announced successful completion of its first
six-month implant evaluation, including no observations of clinically
significant adverse events, foreign body reactions or other observable
clinical effects during the implantation period. The independent histological
analysis now confirms those clinical observations.
The findings are consistent with earlier stages of the LFC-SEN-002 study,
where histological analyses following 12-week implantations similarly
demonstrated favorable tissue response without evidence of adverse biological
effects. The latest results therefore extend Lifecare's documented in-vivo
biocompatibility experience from 12 weeks to six months.
The pathology assessment confirms a favorable tissue response following six
months of continuous implantation and further supports Lifecare's growing body
of evidence regarding long-term implant biocompatibility.
"These results further strengthen our confidence in the long-term
biocompatibility of the Lifecare implant platform," said Joacim Holter, Chief
Executive Officer of Lifecare ASA.
"We have now extended favorable biopsy and pathology findings from 12 weeks to
six months while continuing to observe only limited and expected local tissue
response. Combined with the previously reported operational performance of the
implant, these findings represent another important step in de-risking our
technology platform and another important step in de-risking our technology
platform and strengthening the foundation for future clinical and commercial
execution."
The results further support Lifecare's development program for both veterinary
and human applications and strengthen the biological validation of the
company's long-term implant platform.
The histological examination of tissue samples collected at explantation
demonstrated normal connective tissue, adipose tissue and vascular structures
surrounding the implantation site. The assessment identified only limited
localized inflammatory response and mild fibrosis, with no findings indicative
of clinically significant foreign body reaction, implant rejection, extensive
inflammatory response or other adverse biological tissue effects.
The pathology findings follow Lifecare's announcement on 10 June 2026 that the
company's first six-month implant remained operational throughout the
implantation period, continued to communicate with external equipment
following explantation, and showed no visible mechanical damage upon
microscopic inspection. The company also reported no clinically significant
adverse events, foreign body reactions or other observable clinical effects
during the six-month implantation period.
The explanted implant will undergo laboratory evaluation, including assessment
of sensor performance, chemistry status, membrane condition and long-term
implant durability following six months in vivo.
Two additional implants manufactured from the same reproducible production
batch remain active in the ongoing study and continue to progress toward
similar implantation durations, providing further opportunity to evaluate
repeatability and long-term performance.
The results generated through LFC-SEN-002 continue to provide important input
supporting Lifecare's product development, manufacturing scale-up activities,
regulatory pathway and future commercialization plans.
About LFC-SEN-002
LFC-SEN-002 is an ongoing longevity and performance study evaluating
Lifecare's implantable CGM technology in dogs. The study focuses on
biocompatibility, system stability and in-vivo signal behaviour and supports
both veterinary product development and future human clinical programs. The
study is conducted under veterinary supervision in cooperation with the
Faculty of Veterinary Medicine, Department of Companion Animal Clinical
Sciences at the Norwegian University of Life Sciences (NMBU).
About us
Lifecare ASA is a medical sensor company developing technology for sensing and
monitoring of various body analytes. Lifecare's focus is to bring the next
generation of Continuous Glucose Monitoring systems to market. Lifecare
enables osmotic pressure as sensing principle. Lifecare's sensor technology is
suitable for identifying and monitoring the occurrence of a wide range of
analytes and molecules in the human body and in pets.
Contacts
For further information, please contact:
Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40
Petter Nielsen, CFO, petter.nielsen@lifecare.no, +47 92 24 74 64
CEO\, joacim.holter@lifecare.no\, +47 40 05 90 40\
Petter Nielsen\, CFO\, petter.nielsen@lifecare.no\, +47 92 24 74 64\